{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:29:51Z","timestamp":1794932991937,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","award":["AS-KPQ-111-KNT"],"award-info":[{"award-number":["AS-KPQ-111-KNT"]}],"id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vaccine.2025.127216","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:09:49Z","timestamp":1747177789000},"page":"127216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue"],"prefix":"10.1016","volume":"57","author":[{"given":"Monika","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Han","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jane","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127216_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2024.105710","article-title":"Dengue virus: etiology, epidemiology, pathobiology, and developments in diagnosis and control \u2013 a comprehensive review","volume":"127","author":"Pourzangiabadi","year":"2025","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0010","article-title":"Understanding antibody-dependent enhancement in dengue: are afucosylated IgG1s a concern?","volume":"19","author":"Teo","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.127216_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12929-024-01030-9","article-title":"Dengue virus pathogenesis and host molecular machineries","volume":"31","author":"Sinha","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2025.127216_bb0020","series-title":"Dengue and severe dengue","author":"WHO","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127216_bb0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4269\/ajtmh.23-0717","article-title":"Clinical manifestations of dengue in children and adults in a Hyperendemic region of Colombia","volume":"110","author":"Salazar Fl\u00f3rez","year":"2024","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127216_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00284-020-02284-w","article-title":"Current understanding of the pathogenesis of dengue virus infection","volume":"78","author":"Bhatt","year":"2021","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0035","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","volume":"2","author":"Guzman","year":"2016","journal-title":"Dengue infection Nature Reviews Disease Primers"},{"key":"10.1016\/j.vaccine.2025.127216_bb0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Molecular therapy Methods & clinical development"},{"key":"10.1016\/j.vaccine.2025.127216_bb0045","series-title":"First FDA-approved vaccine for the prevention of dengue disease in endemic regions","author":"FDA","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127216_bb0050","series-title":"Dengue Vaccine","author":"CDC","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127216_bb0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40259-022-00531-z","article-title":"Dengue Vaccines: An Update","volume":"36","author":"Torres-Flores","year":"2022","journal-title":"BioDrugs\u202f: clinical immunotherapeutics, biopharmaceuticals and gene therapy"},{"key":"10.1016\/j.vaccine.2025.127216_bb0060","series-title":"Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia\u00ae) in the state of Paran\u00e1, Brazil: integrating case-cohort and case-control designs. The lancet regional health \u2013 Americas.","first-page":"35","author":"Diaz-Quijano","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127216_bb0065","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.127216_bb0070","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1473-3099(21)00753-2","article-title":"Dengue vaccines: where are we now and where we are going?","volume":"22","author":"Amorim","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127216_bb0075","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127216_bb0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00103-019-03060-3","article-title":"Dengue vaccine development: status and future","volume":"63","author":"Wilder-Smith","year":"2020","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"10.1016\/j.vaccine.2025.127216_bb0085","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127216_bb0090","series-title":"Takeda Announces Voluntary Withdrawal of U.S. Biologics License Application (BLA) for Dengue Vaccine Candidate TAK-003","author":"Takeda","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127216_bb0095","series-title":"WHO prequalifies new dengue vaccine","author":"WHO","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127216_bb0100","unstructured":"Pecci, A. Dengue is spreading and Sanofi is pulling the US market\u2019s only vaccine. What\u2019s next?, vol. 24. Biopharmadive; October, 2024."},{"key":"10.1016\/j.vaccine.2025.127216_bb0105","first-page":"55","volume":"8","author":"Thomas","year":"2023","journal-title":"Is new dengue vaccine efficacy data a relief or cause for concern? npj Vaccines"},{"issue":"7936","key":"10.1016\/j.vaccine.2025.127216_bb0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/d41586-022-03546-2","article-title":"Dengue vaccine poised for roll-out but safety concerns linger","volume":"611","author":"Mallapaty","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127216_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127216_bb0120","first-page":"8","article-title":"A recombinant Zika virus envelope protein with mutations in the conserved fusion loop leads to reduced antibody cross-reactivity upon vaccination","author":"Berneck","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127216_bb0125","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1128\/JVI.00316-08","article-title":"Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II","volume":"82","author":"Lai","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003903","article-title":"An epitope-substituted DNA vaccine improves safety and immunogenicity against dengue virus type 2","volume":"9","author":"Tang","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127216_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.945706","article-title":"Comparative immunogenicity of an mRNA\/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques","volume":"13","author":"Valentin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2025.127216_bb0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.adn4955","article-title":"A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection","volume":"386","author":"Alameh","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127216_bb0150","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1099\/vir.0.006874-0","article-title":"On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes","volume":"90","author":"Rajamanonmani","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0155","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1073\/pnas.1317350111","article-title":"Dengue virus envelope protein domain I\/II hinge determines long-lived serotype-specific dengue immunity","volume":"111","author":"Messer","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127216_bb0160","doi-asserted-by":"crossref","first-page":"6803098","DOI":"10.1155\/2016\/6803098","article-title":"Dengue fever: causes, complications, and vaccine strategies","volume":"2016","author":"Khetarpal","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2025.127216_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/25151355211015839","article-title":"Dengvaxia: the world\u2019s first vaccine for prevention of secondary dengue","volume":"9","author":"Tully","year":"2021","journal-title":"Therapeutic advances in vaccines and immunotherapy"},{"key":"10.1016\/j.vaccine.2025.127216_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.11.082","article-title":"An mRNA vaccine protects mice against multiple tick-transmitted Flavivirus infections","volume":"25","author":"VanBlargan","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2025.127216_bb0175","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virs.2022.01.032","article-title":"An mRNA vaccine encoding chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses","volume":"37","author":"Ge","year":"2022","journal-title":"Virol Sin"},{"key":"10.1016\/j.vaccine.2025.127216_bb0180","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127216_bb0185","first-page":"9","article-title":"mRNA Vaccines against Flaviviruses","author":"Wollner","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127216_bb0190","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2025.127216_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122256","article-title":"An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization","volume":"627","author":"Hsu","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2025.127216_bb0200","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0205","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0210","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3389\/fimmu.2020.01252","article-title":"Anti-dengue vaccines: from development to clinical trials","volume":"11","author":"Pinheiro-Michelsen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127216_bb0215","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.virs.2022.07.003","article-title":"A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice","volume":"37","author":"He","year":"2022","journal-title":"Virol Sin"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:42:27Z","timestamp":1762278147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25005134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"alternative-id":["S0264410X25005134"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127216","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127216"}}